| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2024―Jul―19 |
111 The number needed to biopsy for cutaneous melanoma in residency clinics during the COVID-19 era |
J. Kibbie, S. Zita, C. Armstrong |
| 2 |
[GO] |
2024―Jul―19 |
247 Biologics protect psoriasis patients from being exacerbated by COVID-19 infection |
Y. Zheng, X. Chen |
| 3 |
[GO] |
2024―Jul―19 |
117 A cross-sectional analysis of photodynamic therapy use and medicare expenditures amongst dermatologists before and during the COVID-19 pandemic |
S. Neman, N. Ugwu, J. Trinidad |
| 4 |
[GO] |
2024―Jul―19 |
206 Non-evidence based use of hydroxychloroquine during the COVID-19 pandemic and spike in reports of pemphigus; A disproportionality analysis of the FDA adverse event reporting system (FAERS) |
J. Baroukhian, K. Seiffert-Sinha, A.A. Sinha |
| 5 |
[GO] |
2024―Jul―19 |
540 Covid-19-related alterations in racial disparities in dermatology practice patterns |
S. Cui, L. Zhang, Y. Xie, B. Pentland, A.P. Pentland, J. Ryan Wolf |
| 6 |
[GO] |
2024―Feb―21 |
Autophagy during Severe Acute Respiratory Syndrome Coronavirus 2 Induced Leukocytoclastic Vasculitis: New Insights |
Nesrine Brahimi, Vincent Piguet |
| 7 |
[GO] |
2023―Nov―06 |
3 Hand-foot-vulva pustule After COVID-19 inactive vaccine |
Y. Xie, B. Yin |
| 8 |
[GO] |
2023―Nov―06 |
245 A rare case of erythrodermic sarcoidosis with systemic involvement after COVID-19 vaccination |
B. Lapolla, E. Gordon, O. Adeuyan, C. Schreidah, L. Fahmy, C. Magro, L. Geskin |
| 9 |
[GO] |
2023―Nov―06 |
49 A pink nodule developed after COVID-19 vaccine |
C. Li, Y. Feng |
| 10 |
[GO] |
2023―Nov―06 |
17 New-onset bullous pemphigoid after SARS-CoV-2 infection |
S. Zhoi |
| 11 |
[GO] |
2023―Aug―12 |
SARS-CoV-2 induced vasculitic skin lesions are associated with massive spike protein depositions in autophagosomes |
Andrea Gawaz, Michael Schindler, Elena Hagelauer, Gabriela Blanchard, Simon Riel, Anneli Vollert, Michel Gilliet, Luisa Unterluggauer, Georg Stary, Isabella Pospischil, Wolfram Hoetzenecker, Birgit Fehrenbacher, Martin Schaller, Emmanuella Guenova, Stephan Forchhammer |
| 12 |
[GO] |
2023―Apr―17 |
691 Visualization of Covid-19 pandemic influence on healthcare routines in dermatology using electronic health record data |
J. Ryan Wolf, L. Zhang, Y. Xie, A. Pentland, B.T. Pentland |
| 13 |
[GO] |
2023―Apr―17 |
576 Gender disparities in isotretinoin prescribing patterns for pediatric patients before and during the COVID-19 pandemic |
A.J. Tan, J. Xia, D. Kroshinsky |
| 14 |
[GO] |
2023―Apr―17 |
453 Limited effect of reducing pulmonary tuberculosis incidence amid mandatory facial masking for COVID-19 |
E. Lin, H. Tu, C. Hong |
| 15 |
[GO] |
2023―Apr―17 |
403 Updated findings from the Global HS COVID-19 Registry |
H. Naik, R. Alhusayen, S. Guilbault, J. Ingram, M. Lowes, A. Marzano, B. Villumsen, C. Yannuzzi |
| 16 |
[GO] |
2023―Apr―17 |
228 Impact of COVID-19 and PPE measures on occupational skin disease in healthcare workers |
S. Chawla, M. Chawla, M. Fugger, C. Moore-gillon, R. Watchorn |
| 17 |
[GO] |
2023―Apr―17 |
227 Immune response and allergenic components of COVID-19 vaccines induced delayed cutaneous reactions |
C. Tsai, W. Chung, C. Chen |
| 18 |
[GO] |
2023―Apr―17 |
226 Characteristics of immune response profile in patients with immediate allergic and autoimmune urticarial reactions induced by COVID-19 vaccines |
C. Wang, C. Chen, W. Chung |
| 19 |
[GO] |
2023―Apr―17 |
222 Severe COVID-19 infection predisposes patients to greater burden of hair loss |
S. Patel, M. Colavincenzo |
| 20 |
[GO] |
2023―Apr―17 |
224 Humoral immune response to COVID-19 vaccination in psoriasis patients on biologic therapy is impaired compared to healthy controls |
H. Puschmann, W. Milz, S. Emmert, R. Panzer |
| 21 |
[GO] |
2023―Apr―17 |
223 Spectrum changes of pediatric dermatological disorders before and during the COVID-19 pandemic in China: A single national center for children’s health experience |
Y. Liu, L. Ma |
| 22 |
[GO] |
2023―Apr―17 |
221 Impact of the COVID-19 surge on phototherapy in Taiwan: Experience from a university hospital |
C.E. Lan, K. Chu |
| 23 |
[GO] |
2023―Apr―17 |
220 Dynamic and spatial transcriptional responses in COVID-19-related chilblains |
M. Tihy, S. Matar, P. Sohier, N. Dupin, S. Aractingi, B. Oulès |
| 24 |
[GO] |
2023―Apr―17 |
156 COVID-19 vaccine is a risk factor accelerating time to bullous pemphigoid onset |
A. Pira, F. Mariotti, F. Moro, A. Panebianco, S. Pallotta, B. Didona, G. Di Zenzo |
| 25 |
[GO] |
2023―Apr―17 |
219 Clinical and immunological impact of booster immunization with recombinant mRNA vaccines for SARS-CoV-2 in patients with pemphigus and bullous pemphigoid |
A. Mesas Fernández, F. Solimani, E. Bodner, M. Carevic-Neri, T. Jakovljevicova, A. Philipp, A. Nast, M. Worm, F. Hilke, K. Meier, K. Ghoreschi |
| 26 |
[GO] |
2023―Apr―17 |
225 Enhanced TLR7 immunity drives innate protection against SARS-CoV-2 with chilblains as collateral damage. |
A. Yatim, F. Saidoune, J. Di Domizio, R. Jenelten, A. Joncic, M. Morren, C. Conrad, J. Casanova, M. Gilliet |
| 27 |
[GO] |
2023―Apr―01 |
T Cells Remember SARS-CoV-2 in Rituximab-Treated Pemphigus Vulgaris |
David O. Croitoru, Vincent Piguet |
| 28 |
[GO] |
2023―Jan―28 |
SARS-CoV-2 vaccination effectiveness in Rituximab-treated patients affected by Pemphigus Vulgaris |
C. Fenizia, C. Moltrasio, L. Ottobrini, O. Utyro, G. Genovese, C. Vanetti, D. Trabattoni, A.V. Marzano |
| 29 |
[GO] |
2022―Nov―18 |
076 Risk of severe COVID-19 associated with immune-modifying drugs: data from PsoProtect and Global Rheumatology Alliance registries |
P Study Group, G. Rheumatology Alliance Study Group |
| 30 |
[GO] |
2022―Nov―18 |
160 Selected psychological stress and cognitive function parameters in patients suffering from COVID-19 induced telogen effluvium |
K. Tomaszewska, J. Lawniczak, B. Tarkowski, J. Dudek, A. Zalewska-Janowska |
| 31 |
[GO] |
2022―Nov―18 |
063 Autoimmunity and disease outcomes of COVID-19, lessons from vitiligo patients |
N. Post, M. Bekkenk, R. Luiten |
| 32 |
[GO] |
2022―Nov―18 |
073 Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune modifying therapies: a nationwide cohort study in the OpenSAFELY platform |
S. Langan, C. Smith, T. Collaborative |
| 33 |
[GO] |
2022―Nov―18 |
147 Cutaneous Manifestations on Covid-19 Patients: A Systematic Review |
M. Trifitriana, R. Mulawarman |
| 34 |
[GO] |
2022―Nov―18 |
369 Single-cell RNA sequencing analysis of a COVID-19-associated maculopapular rash in a psoriasis patient treated with ustekinumab |
K. Rindler, M. Drach, L. Shaw, W. Weninger, M. Farlik, C. Jonak, P.M. Brunner |
| 35 |
[GO] |
2022―Nov―18 |
168 New considerations regarding vesicular rashes associated with SARS-CoV2 infection and Koebner phenomenon |
A.L. Tatu, T. Nadasdy, F.C. Bujoreanu, E.B. Niculet, L.C. Nwabudike, D. Radaschin |
| 36 |
[GO] |
2022―Aug―24 |
Monkeypox: Considerations as a New Pandemic Looms |
Matthew G. Brewer, Stephanie R. Monticelli, Brian M. Ward |
| 37 |
[GO] |
2022―Jul―20 |
205 COVID-19 complications in vitiligo patients: A multicenter study |
R. Raiker, S. Salingaros, H. Pakhchanian, M. Helm |
| 38 |
[GO] |
2022―Jul―20 |
267 Impact of COVID-19 healthcare disruption on delays in melanoma treatment in rural and urban Iowa |
A. Munjal, M. Fitzhugh, M. Walsh, P. Gorrepati, R. Tripathi, V. Liu, J.G. Powers |
| 39 |
[GO] |
2022―Jul―20 |
157 Severity of COVID-19 in patients with dermatomyositis: A single center, retrospective observational cohort study |
J.S. Johnson, A. Nowacki, J. Narang, S. Young, A. Fernandez |
| 40 |
[GO] |
2022―Jul―20 |
160 Halved incidence of scrub typhus after travel restriction to confine a surge of COVID-19 in Taiwan in 2021 |
E. Lin, H. Tu, C. Hong |
| 41 |
[GO] |
2022―Jul―20 |
LB897 The risk of COVID-19 infection in patients with alopecia areata |
A. Oulee, S. Ahn, S. Shahsavari, A. Martin, J.J. Wu |
| 42 |
[GO] |
2022―Jul―20 |
270 Impact of COVID-19 infection on hidradenitis suppurativa activity |
M.E. Torpey, A. Nosrati, K.L. Campton, S.R. Cohen |
| 43 |
[GO] |
2022―Jul―20 |
168 COVID-19 mRNA vaccine booster cutaneous reactions reported to the AAD/ILDS dermatology registry |
S. Prasad, D.E. McMahon, A. Tyagi, R. Singh, R. Ali, H.W. Lim, L.P. Fox, K. Blumenthal, G. Hruza, L.E. French, E. Freeman |
| 44 |
[GO] |
2022―Jul―20 |
173 Analyzing the impact of COVID-19 on trends in the dermatology literature |
R. Ali, S. Prasad, R. Singh, L. Abdelrahman, R. Kankaria, S. Singh, S. Mehta, V. Mroz, E. Freeman |
| 45 |
[GO] |
2022―Jul―20 |
395 Utilization of teledermatology services for dermatological diagnoses during the COVID-19 pandemic |
A. He, T.T. Kim, K. Nguyen |
| 46 |
[GO] |
2022―Jul―20 |
387 Consumer attitudes, knowledge, and behavior towards aging skin during the COVID-19 pandemic |
L. Yang, J. Knoll, R.V. Kundu |
| 47 |
[GO] |
2022―Jul―20 |
357 Skin cancer treatment delays during the COVID-19 pandemic |
C.B. Lau, K. Yang, C.X. Pan, W.C. Lau, B. Kassamali, V. Nambudiri |
| 48 |
[GO] |
2022―Jul―20 |
347 Patient interest in Mohs surgery telehealth services beyond the COVID-19 pandemic |
A. Munjal, R. Tripathi |
| 49 |
[GO] |
2022―Jul―20 |
384 Impact of the COVID-19 pandemic on dermatology visits among older adults and racial and ethnic minorities |
N. Rizk, M.B. Mathur, J. Ko, A. Chiou, I. de Vere Hunt, S. van Egmond, E. Linos |
| 50 |
[GO] |
2022―Jul―20 |
LB1032 Influence of the covid-19 pandemic on emergency room usage for dermatologic ailments |
S. Gotewal, A. Good, M. Wilkerson |
| 51 |
[GO] |
2022―Jul―20 |
LB955 Adherence in dermatology during the COVID-19 pandemic: A review |
S.G. Bridgeman, P.O. Perche, S.R. Feldman |
| 52 |
[GO] |
2022―Jul―20 |
145 Erythema multiforme in COVID-19 patients and following COVID-19 vaccination |
F. Etaee, M. Basiri, T. Naguib, S. Daveluy |
| 53 |
[GO] |
2022―Jul―20 |
422 Keratinocyte media differences uncovered during COVID-19 supply shortages |
E.M. Pope, M.C. Moran, M.G. Brewer, L.A. Beck |
| 54 |
[GO] |
2022―Jul―20 |
359 Public sunscreen dispenser distribution in the United States: Continued COVID-19 trends during 2021 |
M.D. Szeto, R. Kokoska, J. Maghfour, C. Rundle, C. Presley, T. Harp, A. Hamp, V. Wegener, J. Hugh, R. Dellavalle |
| 55 |
[GO] |
2022―Jul―20 |
366 Comparing patient perspectives towards treatment for alopecia areata before and during COVID-19 using social media data mining |
J. Jueng, V. Bhupalam, A. Su, C.M. Infante, L. Dupuis, S. Shaikh, R. Dellavalle, I. Brooks, O. Burton, J. Solomon |
| 56 |
[GO] |
2022―Jul―20 |
265 Evaluating the safety and effectiveness of the COVID-19 vaccination among pediatric atopic dermatitis patients |
H. Pakhchanian, R. Raiker, K. Jenkins, L. Shen |
| 57 |
[GO] |
2022―Jul―20 |
260 Responses following COVID-19 vaccination in patients with autoimmune skin disease |
G. Sprow, M. Afarideh, J. Dan, E. Keyes, M. Grinnell, J. Concha, T. Vazquez, D. Diaz, N. Kodali, V. Werth |
| 58 |
[GO] |
2022―Jul―20 |
262 Safety and efficacy of the COVID-19 vaccine among fully vaccinated and boosted skin cancer patients |
R. Raiker, H. Pakhchanian, M. Deng |
| 59 |
[GO] |
2022―Jul―20 |
149 Proposing a standardized assessment of COVID-19 vaccine cutaneous reactions |
R. Singh, R. Ali, S. Prasad, K. Blumenthal, E. Freeman |
| 60 |
[GO] |
2022―Jul―20 |
LB926 COVID-19 vaccine hesitancy in a cohort of hidradenitis suppurativa patients |
M. Torpey, A. Nosrati, K.L. Campton, S. Cohen |
| 61 |
[GO] |
2022―Jul―20 |
LB923 COVID-19 vaccine immunity in hidradenitis suppurativa patients receiving TNF-alpha inhibitors |
A. Nosrati, M.E. Torpey, G.D. Ball, N. Shokrian, K.L. Campton, S.R. Cohen |
| 62 |
[GO] |
2022―Jul―20 |
322 Is social media spreading misinformation on the COVID-19 vaccines within the psoriasis community? |
D. Yee, C. Zagona-Prizio, S. Khan, S. Khan, N. Maynard, M.D. Mehta, R. Reddy, A.W. Armstrong |
| 63 |
[GO] |
2022―Jul―20 |
LB1043 COVID-19-associated pruritus is non-histaminergic mediated |
A. Labib, L.A. Nattkemper, A. Vander Does, T. Ju, S. Cacciapuoti, M. Vastarella, G. Fabbrocini, G. Yosipovitch |
| 64 |
[GO] |
2022―Jul―20 |
801 Experience of advanced dermatology and cosmetic surgery clinics providers with teledermatology amidst the coronavirus disease-19 lockdown |
C.M. Infante, J. Jueng, A. Su, B. Maner, T. Harding, S. Eubanks, J. Solomon |
| 65 |
[GO] |
2022―Jul―20 |
LB981 Pandemic associated chilblain-like lesions result from an inducible type 1 interferon response to SARS-CoV-2 |
L. Arkin, A. Costa da Silva, J. Mays |
| 66 |
[GO] |
2022―Jul―20 |
850 Potential role of skin in SARS-CoV-2 infection |
D. Chudakova, A. Klopot, B. Shi, P. Bhalla, L.C. Tsoi, B.E. Perez White, I. Budunova |
| 67 |
[GO] |
2022―Jul―20 |
389 Impact of the COVID19 pandemic on the execution of real world, pragmatic trials: The LITE study experience |
B. Hefele, K. Duffin, L. Howard, D.B. Shin, J.M. Gelfand |
| 68 |
[GO] |
2021―Oct―08 |
067 BELCOMID: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases |
T. Hillary, A. Van Laethem, F. Castelijns, S. Vermeire, J. Geldof, M. Ferrante, K. De Vlam, P. Verschueren, J. Sabino, T. Lobaton, H. Lapeere, J. Lambert |
| 69 |
[GO] |
2021―Oct―08 |
072 Covid-19 and male androgenetic alopecia: Systematic investigation of a potential epidemiological and genetic association |
S.K. Henne, L.M. Hochfeld, C. Maj, M.M. Nöthen, S. Heilmann-Heimbach |
| 70 |
[GO] |
2021―Oct―08 |
065 Application of teledermatology during the first wave of the COVID-19 pandemic in Hungary |
A. Jobbágy, F. Meznerics, K. Farkas, S. Bozsányi, L. Fesus, N. Kiss, K. Lorincz, N. Wikonkal, M. Sárdy, A. Bánvölgyi |
| 71 |
[GO] |
2021―Oct―08 |
055 The impact of methotrexate and targeted immunosuppression on cellular and humoral immune responses to COVID-19 vaccine BNT162b2: a cohort study |
S.K. Mahil, K. Bechman, A. Raharja, C. Domingo-Vila, M. Brown, A. Cope, M. Malim, E. Pollock, J. Seow, J. Barker, S. Norton, J. Galloway, K. Doores, T. Tree, C. Smith |
| 72 |
[GO] |
2021―Oct―08 |
245 Demodex folliculorum interaction with SARS-CoV2 from a chitin-lipid perspective |
A.L. Tatu, T. Nadasdy, F.C. Bujoreanu, D. Radaschin, L.C. Nwabudike |
| 73 |
[GO] |
2021―Aug―19 |
LB761 Clinical outcomes in Pemphigoid and Pemphigus patients with COVID-19 |
H. Pakhchanian, R. Raiker, J. Wang, K. Phan |
| 74 |
[GO] |
2021―Aug―19 |
LB751 COVID-19 complications in patients with Hidradenitis Suppurativa: A multicenter study |
R. Raiker, H. Pakhchanian, K. Phan |
| 75 |
[GO] |
2021―Aug―19 |
LB767 A multicenter analysis of patients using telemedicine for dermatological conditions during the COVID-19 pandemic |
R. Raiker, H. Pakhchanian, M. Baker, E. Hochman, M. Deng |
| 76 |
[GO] |
2021―Aug―19 |
LB723 Face skin changes caused by face mask during the COVID-19 pandemic |
S. Park, J. Han, Y. Yeong, N. Kang, B. SUH, E. Kim |
| 77 |
[GO] |
2021―Aug―19 |
LB768 Adult and pediatric emergency department visits for dermatological conditions during the COVID-19 pandemic: A multicenter analysis |
H. Pakhchanian, R. Raiker, K. Russomanno, M. Deng |
| 78 |
[GO] |
2021―Aug―19 |
LB771 Racial and Ethnic Disparities in COVID-19-Related Infection in Patients with Psoriasis: A Cross-Sectional Study |
C. Nguyen, S. Shwe, K. Yale, A. Ghigi, K. Zheng, N. Mesinkovska, T. Bhutani |
| 79 |
[GO] |
2021―Aug―19 |
LB740 SARS-CoV-2-associated ‘covid toes:’ multiplex immunofluorescent characterization of pathophysiology |
J.J. Moon, A. Costa da Silva, J.M. Tran, C. Kim, R. Sharma, M. Hinshaw, B.E. Shields, E. Brooks, E.W. Cowen, A. Singh, B. Drolet, J. Mays, L. Arkin |
| 80 |
[GO] |
2021―Aug―04 |
Assessing the risk and outcome of COVID-19 in patients with psoriasis or psoriatic arthritis on biologic treatment: a critical appraisal of the quality of the published evidence |
Stefano Piaserico, Paolo Gisondi, Simone Cazzaniga, Sara Di Leo, Luigi Naldi |
| 81 |
[GO] |
2021―Jul―15 |
From your nose to your toes: A Review of SARS-CoV-2 Pandemic-associated Pernio |
Lisa M. Arkin, John J. Moon, Jennifer M. Tran, Samira Asgari, Cliona O’Farrelly, Jean-Laurent Casanova, Edward W. Cowen, Jacqueline W. Mays, Anne Marie Singh, Beth A. Drolet |
| 82 |
[GO] |
2021―Apr―19 |
255 The risk of contracting COVID-19 after dermatological procedures compared with other medical procedures |
R. Raiker, H. Pakhchanian, A. Baghdjian, V.A. Patel |
| 83 |
[GO] |
2021―Apr―19 |
336 Risks of COVID-19 infection and mortality for patients on biologics |
V. Pahalyants, W. Murphy, N. Klebanov, N. Theodosakis, M. Klevens, E. Lilly, M. Asgari, Y. Semenov |
| 84 |
[GO] |
2021―Apr―19 |
028 Use of systemic immunosuppressive treatment is not related to COVID-19 infection in a retrospective review of patients in Massachusetts |
W. Murphy, N. Klebanov, V. Pahalyants, N. Theodosakis, K. Patel, M. Klevens, E. Lilly, Y. Semenov |
| 85 |
[GO] |
2021―Apr―19 |
316 The impact of COVID-19 on gender representation in academic dermatology publications |
M.D. Szeto, M. Laughter, M.B. Maymone, T.E. Sivesind, C.L. Presley, S.M. Lada, K.J. Pulsipher, R. Dellavalle |
| 86 |
[GO] |
2021―Apr―19 |
652 Using implementation science to understand teledermatology during the COVID-19 pandemic |
S. Briggs, J. Lipoff, S. Collier |
| 87 |
[GO] |
2021―Apr―19 |
391 Public sunscreen dispensers and consumer sunscreen trends during the COVID-19 pandemic |
J. Maghfour, C. Rundle, M.D. Szeto, C.L. Presley, C. Eason, C. Dunnick, J. Hugh, R. Dellavalle |
| 88 |
[GO] |
2021―Apr―19 |
281 Racial and language disparities in teledermatology visits for acne during the COVID-19 pandemic |
M.S. Lee, B. Kassamali, N. Shah, A. Lachance, V. Nambudiri |
| 89 |
[GO] |
2021―Apr―19 |
461 A review of cutaneous lymphoma outcomes during COVID-19 pandemic at Columbia University |
T. Garcia-Saleem, C. Stonesifer, L. Geskin |
| 90 |
[GO] |
2021―Apr―19 |
433 Increased risk of hospital acquired sacral pressure injuries in COVID-19 patients |
J. Narang, J. Gallop, S. Seck, A.H. Wei, A.S. Nowacki, A.P. Fernandez |
| 91 |
[GO] |
2021―Apr―19 |
441 Cutaneous findings in COVID-19 patients hospitalized at a large urban academic medical center |
S. Chand, R. Rrapi, J. Lo, C. Gabel, S. Song, Z. Holcomb, C. Iriarte, K. Moore, C. Shi, H. Song, F. Xia, D. Yanes, R. Gandhi, V. Triant, D. Kroshinsky |
| 92 |
[GO] |
2021―Apr―19 |
342 Clinical outcomes in COVID-19 patients with Atopic dermatitis |
H. Pakhchanian, R. Raiker, V.A. Patel |
| 93 |
[GO] |
2021―Apr―19 |
338 Clinical outcomes in COVID-19 patients with dermatopolymyositis |
H. Pakhchanian, R. Raiker, A. Qureshi, V.A. Patel |
| 94 |
[GO] |
2021―Apr―19 |
243 Clinical outcomes in COVID-19 patients with varicella zoster virus |
R. Raiker, H. Pakhchanian, A. Gonzalez Lopez, V.A. Patel |
| 95 |
[GO] |
2021―Apr―19 |
011 Systemic hyperinflammation as a driver of maculopapular drug exanthema in severely ill COVID-19 patients? |
Y. Mitamura, D. Schulz, I. Kolm, S. Oro, M. Levesque, E. Maverakis, C. Akdis, M. Brüggen |
| 96 |
[GO] |
2021―Apr―19 |
254 COVID-19 related outcomes in psoriasis and psoriasis arthritis patients |
R. Raiker, H. Pakhchanian, V.A. Patel |
| 97 |
[GO] |
2021―Apr―19 |
032 A multicomponent skin-targeted COVID-19 vaccine elicits robust humoral and cellular immune responses |
S.C. Balmert, Z.G. Ghozloujeh, C.D. Carey, T.L. Sumpter, G. Erdos, E. Korkmaz, L.D. Falo |
| 98 |
[GO] |
2021―Apr―19 |
381 Perspective of psoriatic disease patients on novel COVID-19 vaccines |
G. Gondo, S. Heydon, S. Bell |
| 99 |
[GO] |
2021―Apr―19 |
205 Evaluation of SARS-CoV-2 spike protein response on PI3K agonist-mediated IL-8 release |
C.E. Borchers, A. Thyagarajan, C. Rapp, J.B. Travers, R. Sahu |
| 100 |
[GO] |
2021―Apr―19 |
332 National trends of dermatology procedures during the COVID pandemic |
R. Raiker, H. Pakhchanian, K. Alam, A. Hakopian, V.A. Patel |
| 101 |
[GO] |
2021―Apr―19 |
335 Trends in dermatological prescribing patterns during the COVID pandemic |
H. Pakhchanian, R. Raiker, K. Alam, A. Hou, V.A. Patel |
| 102 |
[GO] |
2021―Apr―19 |
331 Trends and outcomes in patients with malignant skin cancers during the COVID pandemic |
R. Raiker, H. Pakhchanian, A. Hussain, M. Deng |
| 103 |
[GO] |
2021―Apr―19 |
677 Personal protective equipment needs during the COVID-19 pandemic: A survey of medical dermatologists |
S. Chand, R. Rrapi, C. Gabel, Y. Levin, V. Neel, D. Kroshinsky |
| 104 |
[GO] |
2020―Oct―15 |
ACE2 expression on the keratinocytes and SARS-CoV-2 percutaneous transmission, are they related? |
Ruixuan Zhu, Yaqian Shi, Yixin Tan, Rong Xiao |
| 105 |
[GO] |
2020―Sep―02 |
Clinical research post COVID-19: Embracing a new normal |
Joel M. Gelfand, Brooke E. Hefele |
| 106 |
[GO] |
2020―Aug―14 |
The Impact of Covid-19 on Dermatology Clinical Trials |
Sheena Desai, Priya Manjaly, Karen Lee, Sara J. Li, Cyriac Manjaly, Arash Mostaghimi |
| 107 |
[GO] |
2020―May―23 |
High expression of ACE2 on the keratinocytes reveals skin as a potential target for SARS-CoV-2 |
Xiaotong Xue, Zihao Mi, Zhenzhen Wang, Zheng Pang, Hong Liu, Furen Zhang |
